At Glide Technologies, consideration of patient-centric care and the ways to increase patient comfort and adherence to injectable drug regimens have been translated into both novel drug formulation technology and novel delivery device design.
Glide has discovered that the use of certain excipients and hardeners allows stable solid dose formulation of many drugs and vaccines that are normally injected in liquid form.
To administer Glide’s formulations the company has developed a hand-held ‘solid dose injector’ (“SDI®”). In use, all that is required is push the end of the SDI® against the skin. The patented internal mechanism of the SDI® responds to the slight rise in pressure so created by ejecting the drug dose and pushing it into the subcutaneous layer of the skin, all in a fraction of a second.
In order to make the SDI® reusable Glide has developed small disposable cartridges, each of which contains a single dose of drug. It takes only four steps to load a cartridge on to the SDI® and to inject drug through the skin. Glide anticipates that the ease of loading and speed of injection will be features that patients and healthcare workers currently spending minutes injecting liquid drug or vaccine doses will appreciate – hence the likelihood of improved adherence.
Demonstrations, using human volunteers, show that the SDI® use is intuitive and that the SDI® is easy to operate. These and other ‘human factor’ studies carried out by Glide show that volunteers prefer drug delivery by SDI® to injection by needle and syringe.